Business Context and Reporting Period
This Form 8-K reports on the 2026 Annual General Meeting of enGene Therapeutics Inc., held on June 9, 2026. The Company is incorporated in British Columbia and its common shares (ENGN) and warrants (ENGNW) trade on The Nasdaq Stock Market LLC. The Company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
As of the record date of April 28, 2026, there were 66,989,466 Common Shares outstanding. A total of 56,196,302 shares (approximately 83.89%) were present or represented by proxy at the meeting.
Proposal 1: Election of Directors
- Philip Astley-Sparke: 47,112,414 For; 306,821 Withhold; 8,777,067 Broker Non-Votes.
- Ronald H.W. Cooper: 47,329,848 For; 89,387 Withhold; 8,777,067 Broker Non-Votes.
- Dr. William Grossman: 47,408,163 For; 11,072 Withhold; 8,777,067 Broker Non-Votes.
- Michael Heffernan: 47,408,163 For; 11,072 Withhold; 8,777,067 Broker Non-Votes.
Proposal 2: Appointment and Remuneration of Auditor
- For: 56,180,287
- Withhold: 16,015
- Broker Non-Votes: 0
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to disclose the final voting results of the Annual Meeting.
Investor Verification Checklist
- Verify the definitive Proxy Statement filed on May 8, 2026, for detailed descriptions of the director nominees and auditor appointment.
- Confirm the total number of outstanding shares (66,989,466) and the record date (April 28, 2026) against the Company's most recent periodic reports.
- Review the Company's financial status in the most recent 10-K or 10-Q, as this 8-K contains no financial performance data.